Radioimmunotherapy

Radioimmunotherapy + CAR T-cell Therapy for Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Harrison, NY

Phase < 1

Recruiting

Led By Mark B Geyer, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with B-cell acute lymphoblastic leukemia or B lymphoblastic lymphoma (ALL) or chronic myeloid leukemia (CML) in lymphoid blast crisis: ("B-ALL patients")

Patients with Philadelphia chromosome-negative B-cell ALL must have been refractory to at least 1 line of multi-agent chemotherapy or relapsed following at least 1 prior multiagent systemic chemotherapy regimen that included induction and consolidation therapy.

Must not have

ECOG performance status ≥3.

Any history of severe non-ischemic cardiomyopathy with LVEF ≤20%

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 days after treatment

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new way to give CAR T cells, using a lower dose of radiation to prepare the patient's body. They want to find the maximum tolerated dose of the new method.

See full description

Who is the study for?

Adults with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma, who have tried and not responded to previous treatments. They must have a certain level of organ function, no severe heart conditions, and cannot be pregnant. Those with active infections or other serious health issues are excluded.Check my eligibility

What is being tested?

The trial is testing the combination of a radioactive antibody called 131-I apamistamab followed by CAR T-cell therapy in patients with specific types of blood cancer. The goal is to find the highest dose that patients can tolerate without too many side effects.See study design

What are the potential side effects?

Potential side effects may include reactions related to radioactivity exposure from 131-I apamistamab such as nausea and thyroid issues, as well as those associated with CAR T-cell therapy like fever, difficulty breathing, confusion, and weakness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have B-cell acute lymphoblastic leukemia or chronic myeloid leukemia in blast crisis.

show original

Select...

My B-cell ALL did not respond to or has returned after chemotherapy.

show original

Select...

My B-ALL or DLBCL cancer has returned or is not responding to treatment.

show original

Select...

My oxygen levels are 92% or higher without extra oxygen.

show original

Select...

My leukemia did not respond to advanced treatment.

show original

Select...

My cancer has spread to my bones or I have a tumor that shows up on PET scans.

show original

Select...

I am 18 years old or older.

show original

Select...

I have signs of cancer remaining before receiving CAR T-cell therapy.

show original

Select...

I have been diagnosed with a type of lymphoma called diffuse large B-cell.

show original

Select...

My kidneys are functioning well enough to filter waste.

show original

Select...

My cancer affects my B-cells, is CD19 positive, and has not responded to treatment.

show original

Select...

I can take care of myself and perform daily activities.

show original

Select...

My DLBCL or HGBL cancer did not respond to 2+ treatments including anthracycline and CD20 therapy.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have significant difficulty in performing daily activities.

show original

Select...

I have a severe heart condition with very low heart pump function.

show original

Select...

I am not on systemic therapy for an autoimmune disease.

show original

Select...

I am not currently on systemic therapy for graft versus host disease after a transplant.

show original

Select...

I do not have any ongoing serious infections.

show original

Select...

I do not have severe neurological disorders like epilepsy or major brain injuries.

show original

Select...

My heart condition severely limits my daily activities.

show original

Select...

I do not have antibodies against the BC8 treatment.

show original

Select...

My heart's pumping ability is below 40%.

show original

Select...

I do not have any serious heart conditions.

show original

Select...

I have a history of serious irregular heartbeats or fainting spells not caused by dehydration.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days after treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days after treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days after treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Dose-limiting toxicities and maximum tolerated dose of 131-I apamistamab, when given in combination with 19-28z CAR T-cells for treatment of relapsed or refractory B-cell ALL or DLBCL